Matthieu Sarabi

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: November 23, 2025

Biliary tract cancers: topaz-1 up-date, a practice changing study.

Biliary tract cancers: topaz-1 up-date, a practice changing study.

Journal: Hepatobiliary surgery and nutrition

Published: June 01, 2025

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 11, 2023

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 13, 2023

New drug approval: Durvalumab in combinaison with cisplatin and gemcitabine in first-line in patient with advanced biliary tract cancer

New drug approval: Durvalumab in combinaison with cisplatin and gemcitabine in first-line in patient with advanced biliary tract cancer

Journal: Bulletin du cancer

Published: February 08, 2023

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 24, 2022

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.

Journal: Journal of personalized medicine

Published: February 25, 2022

Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.

Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.

Journal: Immunotherapy

Published: September 08, 2021

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.

Journal: Frontiers in oncology

Published: August 10, 2021

Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer.

Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer.

Journal: Journal for immunotherapy of cancer

Published: January 10, 2021

Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.

Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.

Journal: British journal of cancer

Published: December 18, 2020

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

Journal: ESMO open

Published: November 01, 2020

Showing 1-12 of 26

Last Updated: 09/26/2026